BioNTech SE is 1.4x more valuable than NEUROCRINE BIOSCIENCES INC by market capitalization ($22.18 B vs $16.35 B). Every figure below comes from audited SEC filings and refreshed market data.
| Metric | NBIX | BNTX |
|---|---|---|
| Market cap | $16.35 B | $22.18 B |
| US-listed rank | #695 | #582 |
| Revenue (latest FY) | $2.86B | - |
| Net income (latest FY) | $478.60M | - |
| Net margin | 16.7% | - |
| P/E (trailing FY) | 34.2 | - |
| SEC filings | 2,097 | 548 |
BioNTech SE is 1.4x more valuable than NEUROCRINE BIOSCIENCES INC by market capitalization ($22.18 B vs $16.35 B).
Full pages: NEUROCRINE BIOSCIENCES INC and BioNTech SE, or browse the full rankings.